Drug-Price Transparency Won’t End the Patent Games

Late last week, Sandoz Inc., the generics division of Novartis AG, settled a patent lawsuit with AbbVie Inc. over Humira, a so-called biologic drug that treats rheumatoid arthritis and just so happens to be the biggest money-maker in all of pharma. With 2017 sales of $18.4 billion, Humira accounts for an astonishing 65 percent of AbbVie’s revenue.

https://www.bloomberg.com/view/articles/2018-10-16/humira-patents-show-why-fda-s-drug-price-shaming-won-t-work